Home CONTACT Neoplasma 2017 Neoplasma Vol.64, No.3, p.344-350, 2017

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.64, No.3, p.344-350, 2017

Title: Secalonic acid- F inhibited cell growth more effectively than 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo
Author: X. Gao, H. L. Sun, D. S. Liu, J. R. Zhang, J. Zhang, M. M. Yan, X. H. Pan

Abstract: Hepatocellular carcinoma (HCC), one of the most common types of liver cancer, could be treated with 5-fluorouracil (5-FU). Due to its side effects, 5-FU is more often used as the co-administration drug in clinical practice. Secalonic acid-F (SAF), isolated from a fungal strain identified in our lab as Aspergillus aculeatus, showed potent biological activities. The goal of this study was to evaluate the inhibitory effects of SAF on hepatocellular carcinoma and to compare it with that of 5-FU. Results showed that SAF effectively inhibited cell growth with a dose-dependent manner in vitro and in vivo. And the inhibitory effects of SAF were stronger than that of 5-FU. Importantly, the cytotoxicity of SAF to peripheral blood mononuclear cells (PBMC) was similar to that of 5-FU. Furthermore, this study demonstrated that SAF arrested the cell cycle at the G1 phase and induced apoptosis with a dose-dependent manner by activating caspase3 and caspase9 through a mitochondrial pathway. Consequently, SAF may be a better potential candidate compound for human cancer treatment; these results will afford more data for antitumor agent design in detail.

Keywords: Secalonic acid-F, 5-fluorouracil, tumor growth, PBMCs, cell cycle, apoptosis
Published online: 12-May-2017
Year: 2017, Volume: 64, Issue: 3 Page From: 344, Page To: 350

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.